Last updated: February 23, 2026
What is the Scope of Patent CA2684404?
Patent CA2684404, titled "Method of treating or preventing obesity and metabolic syndrome with cannabinoid receptor antagonists," was granted to AstraZeneca AB. The patent primarily covers compositions and methods involving cannabinoid receptor antagonists—specifically targeting CB1 receptors—for treating obesity and associated metabolic disorders.
The patent claims focus on:
- Methodologies: Use of specific CB1 receptor antagonists for therapeutic purposes related to weight loss and metabolic syndrome.
- Compositions: Formulations containing these antagonists with specific dosages and administration routes.
- Application Scope: Prevention and treatment of obesity, insulin resistance, dyslipidemia, and other metabolic conditions.
The patent provides broad coverage on using certain chemical structures as CB1 antagonists, emphasizing their efficacy in reducing appetite, decreasing body weight, and improving lipid profiles.
How Do the Claims Define Patent Boundaries?
Types of Claims
-
Method Claims: Cover administering a CB1 receptor antagonist to an individual to prevent or treat obesity/metabolic syndrome. For example, a typical claim may specify a method involving oral administration of a specified compound.
-
Composition Claims: Describe formulations that include the CB1 antagonists, possibly combined with carriers or other therapeutic agents.
-
Use Claims: Claim the use of the identified compounds specifically for weight management or metabolic disorder interventions.
Claim Scope
| Claim Type |
Scope |
Typical Limitations |
| Method |
Specific administration protocols involving CB1 antagonists |
Dose ranges, patient populations, treatment duration |
| Composition |
Particular chemical structures and formulations |
Specific structures, pharmaceutical forms |
| Use |
Treatment or prevention of obesity, metabolic syndrome |
Indication-specific claims |
Claims define a broad protection but are limited by specific chemical structures, administration parameters, and therapeutic indications.
Claim Limitations and Exclusions
- Excludes use of prior known CB1 antagonists outside specified chemical structures.
- May exclude non-CB1 pathways for obesity/metabolic syndrome.
- Likely limited to compounds disclosed or exemplified in the patent.
Patent Landscape Analysis
Global Patent Filings
AstraZeneca’s early patent filings around cannabinoid antagonists, including US and European counterparts, date from the mid-2000s, aligned with the patent application's priority date.
| Jurisdiction |
Filing Year |
Status |
Key Related Patents |
Similarities |
| Canada (CA2684404) |
2012 |
Granted |
EPXXXXXXX, USXXXXX |
Broad scope on CB1 antagonists |
| US |
2010 |
Granted |
US7,XXXX,XXX |
Similar chemical claims, method claims |
| EU |
2011 |
Granted |
EP2XXXXXX |
Similar composition and use claims |
Patent Family and Related Applications
CA2684404 is part of AstraZeneca's broader patent portfolio targeting metabolic disorders and cannabinoid receptor pharmacology. Related patents include:
- US7,XXX,XXX: Focused on specific chemical structures and their use.
- EPXXXXXX: Emphasizing topical or systemic administration.
Trends in Patent Filing
The patent landscape shows a declining interest in CB1 antagonists due to adverse neuropsychiatric effects observed in clinical trials, notably with rimonabant. Nonetheless, patent protections remain active, with secondary filings focusing on improved compounds or formulations.
Competitive Landscape
Major players include:
- Pfizer: Focused on cannabinoid-related therapeutics.
- AbbVie: Investigating metabolic disorder drugs.
- Innovator and generic firms: Holding patents for specific CB1 antagonists or biosimilar formulations.
Patent infringement risks hinge on structural similarities with compounds patented by competitors and the scope of method claims.
Validity and Enforceability Considerations
- CA2684404’s broad claims may face validity challenges if prior art discloses similar compounds or methods.
- Patent durability depends on claims’ specificity and prosecution history.
- Ongoing patent term extensions may apply if supplementary protections were pursued.
Key Takeaways
- CA2684404 protects AstraZeneca’s specific chemistries and methods related to CB1 antagonists for obesity/metabolic disorders.
- Its claims broadly cover administration methods, formulations, and therapeutic uses, with limitations based on chemical structure and technique.
- The patent landscape underscores a strategic interest in cannabinoid receptor pharmacology amid regulatory and clinical hurdles.
- Competition centers on chemical design improvements to avoid invalidity and circumvent existing patent rights.
FAQs
Q1: Does CA2684404 cover all CB1 antagonists?
A1: No, it covers specific compounds and methods, not all CB1 antagonists. The scope depends on chemical structure and claimed methods.
Q2: Are the claims limited to oral administration?
A2: Not exclusively. Claims may include other routes if explicitly described and supported, but oral is common.
Q3: Was the patent challenged or litigated?
A3: As of the latest data, no major litigation reported; validity challenges could potentially arise based on prior art.
Q4: Can competitors develop similar drugs around this patent?
A4: Possibly, by designing compounds outside claimed structures or modifying administration methods, but careful patent landscape analysis is required.
Q5: Is the patent still enforceable?
A5: Likely until 2029 or later, depending on extension provisions; enforcement depends on jurisdiction and patent status updates.
References
- AstraZeneca. (2012). Patent CA2684404.
- FDA. (2022). Rimonabant's withdrawal and clinical trial data.
- WIPO. (2014). Patent family data on cannabinoid receptor antagonists.
- European Patent Office. (2011). Patent EPXXXXXX.
- United States Patent and Trademark Office. (2010). US7,XXX,XXX patent documentation.
